EMD Serono Media Center
Immerse yourself in the fascinating world of a healthcare company. Explore the latest news from the media center and stay up-to-date.
Latest News
View all news-
Press Releases
Pimicotinib Significantly Improved Outcomes for Patients with TGCT in Phase ...
Phase III MANEUVER trial of pimicotinib met its primary endpoint, demonstrating significant improvement in objective response rate in TGCT-patients.
2024/11/12
-
Press Releases
EMD Serono Unveils New MAVENCLAD® Four-Year Data Highlighting Benefits of Early ...
EMD Serono today announced presentations showcasing the long-term safety profile, sustained efficacy data, and durable effect of MAVENCLAD® (cladribine) tablets in individuals with RMS.
2024/09/12
-
Press Releases
Merck KGaA, Darmstadt, Germany Announces First Patient Dosed in Phase III Study ...
The first patient has been dosed in the Phase III MyClad trial (NCT06463587) evaluating the efficacy and safety of oral cladribine for the treatment of generalized Myasthenia Gravis (gMG).
2024/08/29
Media Center
The Media Center is a service for journalists, bloggers and online multipliers that allows you to access news about EMD Serono.
-
Get in Touch
Email UsContact the EMD Serono US Communications Team via email.
-
Media Downloads
Browse and download high-quality images and video footage.Access gallery -
Press Releases
Press ReleasesBrowse our news releases or filter by topic, year, and month.